• Assistant Professor, Department of Radiology, University of British Columbia
• Cardiac Radiologist, St. Paul’s Hospital, Providence Healthcare
• Director, Cardiac CT Core Laboratory, St. Paul’s Hospital
• Primary research interests: CT imaging for procedural planning and optimization of transcatheter heart valve repair and replacement, post-procedural imaging and valve thrombosis, Artificial Intelligence for structural heart CT imaging
• Pioneer in development of CT imaging techniques for valve sizing and determining anatomical risk in transcatheter valve replacement
• Clinical interest: Cardiac cross-sectional imaging for structural heart disease, congenital heart disease and coronary artery disease
• Cardiac CT Core Laboratory:
  • Support of First-in Human Studies, Early Feasibility Studies, Pivotal Studies and Randomized Controlled Trials
  • Current studies (selection): PROGRESS, SUMMIT, ENCIRCLE, VANTAGE, ACCURATE IDE
  • Past studies (selection): PARTNER 3, EVOLUT Low Risk, EARLY TAVR, TENDYNE EFS/CE, ALTERRA

Dr. Philipp Blanke is an Assistant Professor at the Department of Radiology, University of British Columbia and Staff Radiologist at St. Paul’s Hospital, Vancouver. He is the Director of the Cardiac CT Core Lab at St. Paul’s Hospital, which supports clinical trials in the field of transcatheter heart valve replacement and repair in regard to CT imaging for screening and follow up. His major research interest are cardiac CT for planning and optimization of heart valve interventions with a focus on investigational devices.

Dr. Blanke received his medical degree and residency training from the University of Freiburg, Germany. He was previously a staff radiologist at the University of Wuerzburg were he successfully underwent the German habilitations process (Dr. med. Dr. habil.). He completed a fellowship in Advanced Cardiac Imaging at UBC/St. Paul’s Hospital before joining as a staff physician.

Dr. Blanke as authored and co-authored more than 250 manuscript. He has pioneered several imaging concepts for planning of transcatheter aortic and mitral valve replacement, including optimization of sizing and assessing anatomical risk. His laboratory has supported a latitude of clinical trials, ranging from first-in human and early feasibility studies to large multi-center, randomized, controlled trials.